Evommune (EVMN) Return on Capital Employed (2025 - 2026)
Evommune (EVMN) reported Return on Capital Employed of 31.18% for Q1 2026, up 46.36% on a QoQ basis from 58.12% in Q4 2025.
Evommune (EVMN) has 2 years of Return on Capital Employed data on file, last reported at 31.18% in Q1 2026.
- Quarterly Return on Capital Employed changed N/A year-over-year to 31.18% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 31.18% (changed N/A YoY) and the FY2025 annual result came in at 61.14%, changed N/A from the prior year.
- Return on Capital Employed rose to 31.18% in Q1 2026 per EVMN's latest filing, from 58.12% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 31.18% in Q1 2026 and bottomed at 58.12% in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Evommune | 744.11 Mn | 532.65 Mn | - | -31.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.18% |
| Dec 31, 2025 | -58.12% |